EP1385966A2 - Proteines hybrides recombinees et leurs trimeres - Google Patents

Proteines hybrides recombinees et leurs trimeres

Info

Publication number
EP1385966A2
EP1385966A2 EP02769144A EP02769144A EP1385966A2 EP 1385966 A2 EP1385966 A2 EP 1385966A2 EP 02769144 A EP02769144 A EP 02769144A EP 02769144 A EP02769144 A EP 02769144A EP 1385966 A2 EP1385966 A2 EP 1385966A2
Authority
EP
European Patent Office
Prior art keywords
recombinant fusion
component
fusion protein
trimer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02769144A
Other languages
German (de)
English (en)
Inventor
Jürg TSCHOPP
Pascal Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topotarget Switzerland SA
Original Assignee
Apoxis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoxis SA filed Critical Apoxis SA
Publication of EP1385966A2 publication Critical patent/EP1385966A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to recombinant fusion proteins with the property of being able to form trimers, the recombinant fusion proteins having at least one component A and at least one component B, component B having trimerizing properties and component A having biological properties, and trimers of these recombinant fusion proteins. Furthermore, the present invention relates to the use of such trimers for the production of a medicament or their use for in-vitro diagnosis or for the production of an in-vitro diagnostic agent.
  • DNA sequences which code for such a fusion protein, as well as expression vectors and host cells which contain the DNA sequence or the expression vector, are also the subject of the present invention.
  • Proteins that occur physiologically as trimers are abundant in nature. Due to interactions on the surfaces of these proteins that trim trimers in solution, there can be spontaneous or, for example, kinetic delays because of concentration- or milieu-dependent aggregation of proteins. Hydrophobic interactions, hydrogen bonds, covalent bonds, for example disulfide bonds, and / or Coulomb forces are responsible for this.
  • structural motifs can be found with certain proteins, which lead to the formation of specific structure-related intermolecular super secondary structures and thus - in addition to other multimerization states - to protein trimers. The formation of super secondary structures is based on characteristic amino acid sequences of the proteins that form these trimers.
  • coiled-coil triple helices can be mentioned as super-secondary structures, which bring about a trimerization of proteins through interactions of characteristic ⁇ -helices which occur with each of the proteins forming the coiled-coil form.
  • the coiled-coil triple helix as an intermolecular "trimerization domain" of proteins is structurally represented as a three-strand, twisted superhelix.
  • Such coiled-coil motifs with a triple helix character occur particularly in extracellular protein trimers, but very particularly in proteins or protein complexes connective tissue.
  • CMP Cartilage Matrix Protein
  • the structure of collagen fibers is characterized by tropocollagen, which consists of three helical twisted polypeptides.
  • the protofibril of a hair is also made up of a triple helix made of ⁇ -Keratm with the motif "Coiled-Coil", albeit left-handed.
  • the proteins Clq, collagen ⁇ l (X), ⁇ 2 (VII), the wintering protein, ACRP30, the inner ear structural protein, the cerebellin and the multimerin are known as the protein family under the name Clq family have been summarized (Kischore and Reid, Immunopharmacol., 42 (1999) 15-21), which are present as higher aggregates of trimers, for example.
  • the structure of the protein Clq known from the complement system is characterized by monomers, each of which has a globular so-called "head domains and a" collagen-like "helical sequence section.
  • the a mono-coil triple helix forms trimerize the monomers, and six of these Clq trimers in turn form an oligomer, whereby the oligomerization of the protein trimers is based on interactions between the individual coiled-coil triple helices.
  • multi- (oligo-) merized protein complex Clq to a structure called "bouquet", whereby it is ensured that 18 globular, C-terminally arranged "head domains are connected to a hexamer of trimers.
  • Proteins from the class of the collectins are also known from the literature, which are characterized by a collagen-like domain, a neck region and moreover by a globular carboxy-terminal lectin binding domain.
  • the col lectins occur physiologically as oligomers of trimers.
  • the proteins Lung Surfactant Protein A (SP-A) and the mannose binding protein (MBP), each from the Collectine family trimerize through the interactions of their "collagen-like" domain and ultimately exist as hexamers of trimers (Epstein et al., Current Opinion in Immunology, Vol. 8, No. 1, 1996, 29-35).
  • the proteins known under the name Collectine also form oligomers (for example hexamers) of multimers (for example trimers).
  • FasL membrane-arranged FasL is biological, i.e. apoptotic, effective, whereas after the extracellular protein section has been split off from the membrane-bound section (so-called sFasL), this non-membrane-bound sFasL fraction can no longer physiologically produce an apoptotic effect on target cells.
  • sFasL membrane-bound FasL
  • sFasL trimers which - as explained above - are obtained after cleavage from the membrane-containing protein section, nevertheless by the use of cross-linking antibodies can be reactivated with regard to their physiological function.
  • a fusion protein consisting of the trimerization domain from FasL, a short linker sequence and a flag marker (with the flag amino acid sequence (one-letter code) DYKDDDDK) was constructed, expressed, and such non-structural (ie not over specific secondary structure interactions resulting in the formation of a super secondary structure) trimerized fusion proteins cross-linked by antibodies directed against the flag marker
  • the unpublished German patent application DE 19963859 discloses Bieder oligomers of di-, tri-, quattro- or pentamers, ie higher-order aggregates, which are made up of recombinant fusion proteins which comprise two components A and B.
  • the recombinant fusion proteins can have, for example, a TNF cytokine as component A and as Component B is a protein segment that connects the recombinant fusion proteins into higher-order aggregates.
  • trimers of recombinant fusion proteins which have at least one component A and at least one component B, component A comprising a protein or a protein segment with a biological function, in particular with a binding function, and the component B comprises a protein or a protein segment which trimerizes the recombinant fusion proteins without the action of third molecules, ie produces a trimer of biologically active components A.
  • trimers are thus provided which cannot form higher-order aggregates, for example dimers of trimers, but rather in solution essentially, at least 90%, preferably at least 95% and very particularly preferably at least 99% , each based on the total number of trimers, are present as trimerized recombinant fusion proteins.
  • a protein or protein segment with a biological function are, in particular, proteins which have a ligand function, very particularly for antibodies or receptors (i.e.
  • amino acid sequences with covalently or non-covalently coupled active substances for example amino acid sequences with covalently or non-covalently coupled active substances (possibly of an organic-chemical nature)
  • antibodies or sections of antibodies with paratopes or also hormones for example peptide horns.
  • the present invention is based on the knowledge that signal proteins in particular, or whose sections or derivatives are used according to the invention as component A, are only biologically active as higher-order aggregates, but bind to receptors as trimers in vitro and in vivo, but do not bind them activate, but rather competitively occupy the binding sites and can not trigger a biologically activating signal, but only block.
  • cleavage products which comprise the extramembrane, in particular the extracellular protein segments, are preferred as component A of a trimerizing recombinant signal protein.
  • amino acid sequences that can act as antigens can also be used as component A in the recombinant fusion protein.
  • receptors e.g. Receptors from the TNF receptor family (e.g. FasR), or sections or derivatives of such receptors are used that also have a binding function (thus interact as a binding partner with another molecule, e.g. membrane-bound FasL) and i.S. the present invention therefore also fall under the term "ligand". Binding fragments of biological receptors of this type are particularly suitable for use as medicaments when the complementary biological ligand is present in the patient in unphysiologically high concentrations
  • components A which are present in trimers according to the invention can have identical components A (homotrimers) or different components A (heterotrimers), ie different ones recombinant fusion proteins form a trimer according to the invention.
  • proteins with different components A possibly with different biological functions, can be linked in the trimer according to the invention.
  • component A of two recombinant proteins can be identical and the third fusion protein can differ with regard to component A, or all three fusion proteins can also differ with regard to component A.
  • the arrangement, the specific combination and / or the number of components A in the trimer typically finely modulated inhibitory, possibly in combination with activating, effects can be achieved.
  • component A in the recombinant fusion protein is a peptide hormone, a growth factor, a cytokine, an interleukin or a section thereof, preferably a bondable section.
  • functional derivatives of the abovementioned peptides, protein segments and / or proteins can also be used as component A in the recombinant fusion protein which is part of a trimer according to the invention.
  • its component A comprises a receptor, for example a receptor for a peptide hormone, a growth factor, a cytokine, an interleukin, or component A of the fusion protein according to the invention is a section or a Derivative of such a receptor.
  • a receptor for example a receptor for a peptide hormone, a growth factor, a cytokine, an interleukin, or component A of the fusion protein according to the invention is a section or a Derivative of such a receptor.
  • a receptor for a peptide hormone, a growth factor, a cytokine, an interleukin, or component A of the fusion protein according to the invention is a section or a Derivative of such a receptor.
  • FasR hereinafter also referred to simply as Fas
  • Functional derivatives of biologically active proteins, protein segments or peptides are in particular those proteins which maintain the biological function, in particular the binding property to the interaction partner, for example the membrane-bound receptor, but nevertheless have sequence differences from the corresponding native sequences.
  • sequence deviations gene can be one or more insertion (s), deletion (s) and / or substitutions), preference being given to a sequence homology of at least 70% and a sequence homology of at least 85% between the derivative used and the native sequence stronger and at least 90% is very particularly preferred.
  • the term functional derivatives includes those amino acid sequences which have conservative substitution with respect to the physiological sequences. Conservative substitutions are substitutions in which amino acids from the same class are exchanged for one another.
  • amino acids with aliphatic side chains, positively or negatively charged side chains, aromatic groups in the side chains or amino acids whose side chains can form hydrogen bonds for example side chains which have a hydroxyl function.
  • an amino acid with a polar side chain is replaced by another amino acid with a likewise polar side chain or, for example, an amino acid characterized by a hydrophobic side chain is substituted by another amino acid with a likewise hydrophobic side chain (eg serine (threonine) by threonine (serine) or leucine (isoleucine) by isoleucine (leucine)).
  • Insertions and substitutions are possible, in particular, at those sequence positions that do not change the three-dimensional structure or affect the binding region.
  • a change in a three-dimensional structure through insertion (s) or deletion (s) can be easily checked, for example, with the aid of CD spectra (circular dichroism spectra) (Urry, 1985, Absorption, circular dichroism and ORD of Polypeptides, in: Modern Physical Methods in Biochemistry, Neuberger et al. (ed.), Elsevier, Amsterdam).
  • Suitable methods for producing proteins with amino acid sequences which have substitutions for the (the) native sequences are disclosed, for example, in the publications US Pat. No. 4,737,462, US Pat. No. 4,588,585, US Pat. No.
  • a ligand can therefore also be a protein that is normally referred to as a receptor.
  • a receptor can also "ligand" i.S. of this invention, e.g. when communicating with its interaction partner, e.g. a signaling molecule binds.
  • a trimer of recombinant fusion proteins is particularly preferred when component A in the recombinant fusion protein is a cytokine from the TNF cytokine family, a section of such a TNF cytokine or a functional derivative of a TNF cytokine or a corresponding TNF cytokine section
  • the biological effect of the TNF cytokines used in the target cells by binding to the corresponding receptors in vivo can, for example, produce apoptotic, proliferative or activating effects, but typically only as a trimer ensure binding to the respective receptor, but no longer perform the activating function.
  • the proteins CD40L, FasL, TRAIL, TNF (in particular TNF which binds to the receptor TNF-R2), CD30L and EDA or their sections or derivatives are very particularly preferred.
  • Extracellular sections of the aforementioned membrane-bound TNF cytokines or their functional derivatives are preferably used as component A in the recombinant fusion protein.
  • component A of the recombinant fusion protein is part of the invented Trimers according to the invention is selected from the group consisting of hFasL (AA 139-281), hTRAIL (AA 95-281), hCD40L (AA 116-261) and m or hTNF ⁇ (AA 77-235).
  • Component A selected for a recombinant fusion protein which is to become part of an oligomer according to the invention is already in solution as a trimer.
  • component B will only intensify the trimerization of component A. This situation occurs, for example, when component A, for example a TNF ligand or a section or derivative thereof, which is typically trimerized already in solution, is to be further stabilized in its trimeric form by component B.
  • component A of a recombinant fusion protein as such does not show a timer structure mediated by surface interaction in solution or in vivo
  • component B according to the invention will have to ensure trimerization of component A of the recombinant fusion proteins.
  • the latter typically occurs, for example, when only portions of the native protein are used as component A of the recombinant fusion protein which, as such, cannot trimerize or at least do not exist as trimer in vivo because, for example, the equilibrium is strongly shifted to the side of the monomer is, for example, sections of cytokines, in particular C-terminal sections (for example comprising at least 100 AS (each calculated from the C-terminus), preferably at least 120 AS and particularly preferably at least 150 AS from the C-terminus) of FasL, CD40L, CD30L, TRAIL, EDA or TNF.
  • C-terminal sections for example comprising at least 100 AS (each calculated from the C-terminus), preferably at least 120 AS and particularly preferably at least 150 AS from the C-terminus) of FasL, CD40L, CD30L, TRAIL, EDA or TNF.
  • component A of the recombinant fusion protein can also be an amino acid sequence according to the present invention which is suitable for acting as a carrier for a receptor agonist or receptor antagonist.
  • a small organic chemical molecule active as a pharmacologically active substance can typically be covalently coupled to such an amino acid sequence, for example via an ether linkage to threonine or serine, an amide-like linkage or via an ester linkage.
  • Coupled agonists or antagonists of this type can increase the binding constant of a trimer according to the invention, preferably to values of at least 10 * 9 M "1 , or modulate the biological effect, in particular to increase the inhibitory behavior of a trimer according to the invention, in particular with regard to the inhibition of the triggering of the apoptotic signal cascade.
  • a trimer according to the invention can be used as a carrier of pharmacologically active substances In this way, a pharmacological active ingredient can be selectively brought into the spatial vicinity of certain cells which represent the pharmacological point of attack of these active ingredients by the choice of a corresponding carrier trimer according to the invention.
  • the coupling of such an active ingredient to a FasL trimer the Binding of the FasL trimer blocks the FasR (and thus inhibits apoptosis according to the invention, thus ensuring the cell's survival) while the active substance is applied directly to the target cell
  • the active ingredient combines cytotoxic substances with the trimer that prevent an attack by immune cells against the target cells, for example in the case of degenerative, in particular neurodegenerative, diseases, especially Parkinson's disease or Alzheimer's disease.
  • Parkinson's disease the destruction of the dopamine-producing cells in the substantia nigra can be prevented in this way according to the invention.
  • the use of such systems of the carrier according to the invention and, if appropriate, covalently coupled active component as pharmaceuticals in human or veterinary medicine is disclosed
  • Component B of the recombinant fusion protein will typically be a protein from the family of the Clq proteins or the Collectine.
  • the proteins of the Clq or collectin family are particularly preferred as part of the recombinant fusion protein, namely as component B, when only their trimerization domain but not their oligomerization domain is transcribed or translated as part of the recombinant fusion protein.
  • Component B in the recombinant fusion protein preferably also does not contain the globular "Kop domain which is characteristic of the aforementioned proteins in the native state.
  • the aforementioned component B in a recombinant fusion protein according to the invention will therefore have a sequence which typically only contains, for example, the collagen type Section that contains the functionality for trimerization Formation of a triple helix, but not those sequence sections which also have the ability to enter into a bi- or oligomer structure (for example a tetra- or hexamer of for example triple helices) with other triple helices.
  • a bi- or oligomer structure for example a tetra- or hexamer of for example triple helices
  • the trimerizing fusion protein will only have the domains of the proteins from the families of the Clq proteins or collectins as component B responsible for the trimerization, while their respective "head domains" by other proteins or protein segments which also perform a biological function than Component A.
  • the term "recombinant fusion protein” is therefore to be understood in the context of the present invention in such a way that the at least one component A and the at least one component B in the recombinant fusion protein are artificially fused, ie that a fusion protein as defined by the present invention does not correspond to a naturally occurring protein
  • component B becomes the corresponding sequence segments of the proteins Clq, MBP, SP-A (“lung surfactant protein A”), SP-D (“lung surfactant protein D”), BC (bovine serum ⁇ glutinin), and CL43 (bovine Collectin-43) and / or ACRP30 or functional derivatives of these protein segments.
  • Trimers of recombinant fusion proteins are particularly preferred when component B of the recombinant fusion protein is a protein segment of the Clq protein or the ACRP30 protein with a sequence segment of at least 8 AA length, typically at least 20 AA length from the collagen-like sequence regions which form a triple helix, or has a functional derivative thereof.
  • a very particularly preferred embodiment of the present invention are trimers of recombinant fusion proteins whose component B is an amino acid sequence according to FIG. 1 (framed sequence, AS 45 to 111) or a functional derivative of this murine (m: murine) amino acid sequence (e.g. the analog human sequence or the analog sequence of another mammal) or a section of this sequence
  • Trimers of such fusion proteins which have sequences from different host organisms are particularly preferred. Aggregates according to the invention are very particularly preferred if they originate from chimeric fusion proteins, component A originating from a different animal species than component B. In this way it can be advantageous for component A to be an amino acid sequence from the mouse, rat, pig or a other vertebrates, in particular from a mammal, or a functional derivative thereof and component B is of human origin or vice versa. On the other hand, the sequences of component A and component B in a fusion protein according to the invention, which forms a trimer according to the invention, but also from the same animal species.
  • the recombinant fusion proteins are trimerized by a short amino acid sequence of more than 6 amino acids, preferably from 8 to 30, very particularly preferably from 8 to 20 amino acids, which is present as component B in the recombinant fusion proteins Trimerization of fusion proteins achieved by means of these short amino acid sequences is typically based on the formation of super-secondary structures, in particular on the formation of "coiled-coil" triple helices.
  • all sequence sections of proteins which generate trimers through the formation of super-secondary structures are suitable, for example typical ones Collagen-like triple helices or sections thereof (such as those used for the proteins CMP, COMP, collagen or laminin).
  • component B of the recombinant fusion protein which leads to trimerization should essentially not form any higher aggregates
  • component B should typically not have any cysteine residue which can form an intermolecular disulfide bridge.
  • Component B in a recombinant fusion protein is therefore preferably no cysteine residue or only those cysteine residues which have an intramolecular disulfide bridge, that is to say in the recombinant fusion protein itself have to avoid that under oxidizing conditions a covalent linkage with the at least one cysteine residue of a fusion protein of another trimer can occur.
  • the fusion protein can have additional sequence segments.
  • tag sequences for example at least one flag tag, that is to say the amino acid sequence DYKDDDDK, and / or, for example, at least one His tag (containing several consecutive histidines, for example at least 5). and / or further tag or antigenic sequences.
  • the individual sections (components A, B or tag sequences, where two or more components A can also occur in the fusion protein according to the invention) of a fusion protein according to the invention can be separated from one another by linker sequences.
  • linker sequences (at least 2 AA, preferably at least 5 AA) are used for the structural separation of the various functional components in the recombinant fusion protein and can preferably also take on a "hinge" function, i.e. represent an amino acid sequence of flexible structure.
  • Linkers which contain at least one proteolytic interface which allows component A to be separated from component B are particularly preferred.
  • the proteolytic interface in the linker is preferably a thrombin consensus sequence.
  • Component A can in principle be arranged at the C or N terminal of component B, preferably at the C terminal.
  • the tag sequences can occur at any position of a recombinant fusion protein according to the invention, preferably at the N-pinus.
  • methods which serve to block cellular extramembrane receptors.
  • Such methods are characterized by recombination of at least one component A, which corresponds to a protein or protein segment with a biological function, with at least one trimerizing component B, with first (a) such a recombinant fusion protein is expressed, for example in an expression vector, (b) is isolated and then (c) is added for in vitro investigations of a cell culture, for example a cell suspension.
  • the present method is therefore suitable for protecting cells from apoptotic cell death, for example, for in vitro investigations.
  • Such cells with trimers according to the invention bound according to the method can then be used for further in vitro investigations or also for the production of a medicament.
  • Such cells treated in vitro can be retransplanted.
  • Such a procedure can be used for autoimmune diseases or degenerative diseases in order to protect the cells from apoptotic destruction in vivo.
  • component A is a TNF cytokine, a section of a TNF cytokine or a functional derivative of such a protein or protein section
  • Trimers of the present invention are suitable for the production of a medicament or for the treatment of diseases or disorders for medical use, ie for both human and veterinary use, in particular when component A is a signal protein or a portion of such or a derivative of the protein or section is a wide spectrum of diseases or disorders can be treated with the trimers claimed according to the invention (hetero- or homotrimers). They are used in particular when increased extracellular concentrations of the corresponding physiological ligands or an increase in the number of membrane-bound receptors occur / occur in a clinical picture.
  • trimers according to the invention can be used, for example, for the manufacture of a medicament for the treatment of hyperinflammatory disorders, autoimmune disorders, disorders based on hyperapoptotic reactions, or degenerative, in particular special neurodegenerative diseases (e.g. Parkinson's disease), possibly also viral infections. Trimers according to the invention are particularly suitable when the disease necessitates treatment which would like to prevent the biological action of native cytokines, ie serves to block corresponding cytokine receptors.
  • Examples include: treatment of viral hepatitis (HBV, HCV), Alcohol-induced hepatitis diseases, chelestatic hepatitis, Wilson's disease, hepatitis due to autoimmune disorders, rejection reactions after liver transplantation, GvHD, TEN (toxic epidermal necrolysis), Hashimoto's thyroiditis or multiple sclerosis.
  • HBV viral hepatitis
  • HCV Alcohol-induced hepatitis diseases
  • chelestatic hepatitis Wilson's disease
  • hepatitis due to autoimmune disorders rejection reactions after liver transplantation
  • GvHD TEN (toxic epidermal necrolysis), Hashimoto's thyroiditis or multiple sclerosis.
  • Another object of the present invention are DNA sequences which code for fusion proteins of the aforementioned type. Such DNA sequences are expressed in expression vectors, the corresponding expression vectors which contain a DNA sequence for the fusion proteins according to the invention also being the subject of the invention.
  • the present invention furthermore includes those host cells which are transfected with DNA sequences which code for the fusion proteins according to the invention. In this context, host cells which are transfected with expression vectors are very particularly preferred, the expression vectors in turn containing DNA sequences which code for the fusion proteins according to the invention. All of the aforementioned objects according to this invention can be considered as pharmaceuticals or for the manufacture of a pharmaceutical, in particular for the treatment of diseases which are disclosed in the present patent application, possibly as part of a composition
  • trimers according to the invention or the further objects of the present invention are preferably used in the context of the present invention for the production of a medicament or for the treatment of the aforementioned diseases or disorders such that they are used for parenteral, ie for example subcutaneous, intramuscular, intraarterial or intravenous, or oral or intranasal or anal, intraperitoneal, vaginal or buccal, intracerebral, intraocular administration (injection or infusion), possibly also for topical application.
  • parenteral ie for example subcutaneous, intramuscular, intraarterial or intravenous, or oral or intranasal or anal, intraperitoneal, vaginal or buccal, intracerebral, intraocular administration (injection or infusion), possibly also for topical application.
  • trimers or host cells according to the invention which form trimers according to the invention, or the DNA sequences which code for recombinant fusion proteins which can form trimers, or corresponding expression vectors can in each case serve as medicaments as such or can be used for the production of a medicament. However, they can also be used in combination with other active active ingredient components or pharmaceutical auxiliaries, carriers or additives as medicaments.
  • the trimers according to the invention or the further subject matter of the invention can thus be combined as constituents in combination with pharmaceutically acceptable carriers, auxiliaries and / or additives. According to the present invention, (pharmaceutical) compositions containing articles according to the invention, in particular trimers according to the invention are therefore also disclosed.
  • compositions according to the invention can include filling substances or substances, such as lactose, mannitol, substances for covalently attaching polymers, such as, for example, polyethylene glycol to inhibitors according to the invention, complexing with metal ions or including materials in or on special preparations of polymer compounds, such as, for example, polylactate, polyglycolic acid, hydrogel or on liposomes, microemulsion, micelles, unilamelar or multilamelar vesicles, erythrocyte fragments or spheroplasts.
  • polylactate polyglycolic acid
  • hydrogel or on liposomes such as, for example, polylactate, polyglycolic acid, hydrogel or on liposomes, microemulsion, micelles, unilamelar or multilamelar vesicles, erythrocyte fragments or spheroplasts.
  • the respective embodiments of the compositions are selected depending on the physical behavior, for example with regard to solubility
  • Controlled or constant release of the active ingredient component according to the invention in the composition includes formulations based on lipophilic depots (for example fatty acids, waxes or oils).
  • lipophilic depots for example fatty acids, waxes or oils.
  • coatings of substances or compositions according to the invention containing such substances namely coatings with polymers (for example poloxamers or poloxarnines) are also disclosed.
  • Substances or compositions have protective coatings, for example protease inhibitors or permeability enhancers.
  • Trimers according to the invention are preferably also used in the field of in vitro diagnosis or, for example, for biochemical cleaning processes.
  • fusion proteins are described which are suitable for the trimerization of, provided that the recombinant fusion protein contains at least one component A and at least one component B, component A being a protein or a protein segment with a biological function, in particular with Contains ligand function for antibodies or receptors, and component B contains a trimerizing section or a functional derivative of such a section of a protein, as described above as a component of the trimers according to the invention.
  • component A being a protein or a protein segment with a biological function, in particular with Contains ligand function for antibodies or receptors
  • component B contains a trimerizing section or a functional derivative of such a section of a protein, as described above as a component of the trimers according to the invention.
  • component B of a recombinant fusion protein according to the invention is typically a protein segment selected from the group , consisting of the family of the Clq proteins or the Collectine or of the family of the collagen-like proteins, wherein the component B of the recombinant fusion protein preferably contains only a trimerizing section, but does not have the trimers oligimerizing structure or globular “Kop domain.
  • component B therefore have at least one amino acid sequence with the heptad pattern (abcdefg) n , which structurally forms a helix forming a triple helix, the amino acids of which in positions a and d preferably carry apolar side chains and thereby the formation of the superhelical structure described above, here as a triple helix from three helices allow.
  • sequences from at least one heptad pattern preferably at least two, can originate, for example, from one of the following protein keratin, collagen, Clq, MBP, SP-A, SP-D, BC, CL43 or ACRP30.
  • a functional derivative of such a section of the aforementioned proteins can also be used in the context of the present invention, the definition of a functional derivative selected above for component A correspondingly also valid for component B.
  • Another object of the present invention is an inhibitor which is present as a hexamer (2x3) in vitro by forming a disulfide bridge in solution (ApoFasL-060).
  • this inhibitor is present - possibly in an oxidizing environment - as a trimer or behaves like a trimer and in this way develops inhibitory properties.
  • ApoFasL-060 consists of an N-terminal flag sequence, a linker and a specific linker as well as the AS 103 to 138 from hFasL and the AS 139 to 281 (component A), also from hFasL (see FIG. 1).
  • an inhibitor of the ApoFasL-060 type can also carry, as component A, the corresponding binding sections of other TNF cytokines, for example OX40L, RANKL, TWEAK, Lta, Ltab2, LIGHT, CD27L, 41-BB, GITRL, APPJL, VEGI and BAFF or their sections or derivatives are very particularly preferred are the proteins CD40L, FasL, TRAIL, TNF (in particular TNF which binds to the receptor TNF-R2), CD30L and EDA or their sections or derivatives, in particular their respective human sequences ,
  • TNF cytokines for example OX40L, RANKL, TWEAK, Lta, Ltab2, LIGHT, CD27L, 41-BB, GITRL, APPJL, VEGI and BAFF or their sections or derivatives are very particularly preferred are the proteins CD40L, FasL, TRAIL, TNF (in particular TNF which binds to the receptor TNF-R2),
  • FIG. 1 shows the amino acid sequence of the FasL chimeras according to the invention (FasL-199, FasL-060 and FasL-267) in the one-letter code.
  • the two protein chimeras FasL-199 and FasL-267 contain a component of the protein ACRP30, one Plasma protein that is structurally similar to the complement factor Clq and is produced by adipocytes.
  • the ACRP30 protein has a length of 247 amino acids, with a secretion signal sequence (AS 1 to 17) at the N-terminus, followed by a sequence of 27 amino acids (AS 18 to 44), which is responsible for the oligomerization of the protein
  • AS 1 to 17 secretion signal sequence
  • AS 18 to 44 sequence of 27 amino acids
  • the following section (AS 45 to 110) of the native protein contains 22 collagen-like sequence repeats, which accordingly form the “coiled-coil” domain. This coiled-coil domain ensures trimerization in the native state.
  • FasL-199 was constructed using PCR amplification and contains the complete oligomerization domain of murine ACRP30 (mACRP30) (amino acids 18 to 110). The C-terminal of this is the FasL chimeric protein, the trimerization domain of FasL (amino acids 139 to 281). Linker sequences are located between the N-terminal flag tag and the mACRP30 section and between mACRP30 (component B) and the human hFasL section (component A) (LQ).
  • the Q ⁇ marenprotein FasL-267 largely corresponds to the construct FasL-199, but has a deletion of the mACRP30 section. It does not contain the oligomerization domain (amino acids 18 to 44) of ACRP30.
  • the deletion mutant was prepared by PCR from EST clone AA673154. Deletion of amino acids 18 to 44 of mACRP30 causes the construct to be a trimer, as shown by the gel filtration experiments
  • the ca ⁇ mar protein FasL-060 has a flag sequence at the N-terminus, followed by a linker (GPGQVQLQ), a specific linker that can form a disulfide bridge, the AS 103 to 138 of human FasL (hFasL) and finally as component A AS 139 to 281 from hFasL.
  • GPGQVQLQ linker
  • ApoFasL-060 behaves as a trimer or as a hexamer.
  • FIG. 2 shows in FIG. 2A the activity of ApoFasL-060 and ApoFasL-267 in vitro with regard to the viability of Bjab cells. Plotted on the y axis in each case the absorbance at OD 490 ⁇ m, plotted on the x-axis (in logarithmic representation) is the concentration of the fusion proteins added for the cytotoxicity test. The optical density at 490 nm is a measure of the viability of the cells (high optical density corresponds to a low one apoptotic effect of the added substances and thus a high cell viability).
  • FIG. 2B shows the inhibitory activity of ApoFasL-267 (o) and ApoFasL-060 () in a representation as in FIG. 2A.
  • oligomerized FasL at a concentration of 50 ng / ml was added in all experiments to trigger apoptosis.
  • Figure 2C shows the results of affinity studies, comparing the affinity of FasL-199 and FasL-267 with Bjab cells.
  • ApoFasL-267 and FasL-199 compete with ZB4 antibodies for binding to Fas on BJAB cells.
  • the percentage of bound ZB4 is plotted against the concentration of FasL-199 () or FasL-267 (o).
  • FIG. 3 shows the results of in vivo experiments, namely the effect of ApoFasL-060 inhibition on hepatolysis induced by agonistic anti-Fas antibody J02.
  • FIG. 3A shows the results of experiments in which mice were injected intravenously with either ApoFasL-060 (25 ⁇ g / mouse) or saline (control) before the intravenous injection of 5 ⁇ g J02 antibodies.
  • the filled bars in FIG. 3A represent the serum titers (in U / ml) of ALT and the open bars of AST represents the results of the measurements four hours after iv injection.
  • the right-hand plot shows the result of the control experiment.
  • 3B shows the survival rate of mice that received 10 ⁇ g of J02 antibodies, namely after pretreatment with saline (filled bars) or with ApoFasL-060 (20 ⁇ g) (light gray bars, 2nd in each case from the left) or only with ApoFasL-060 (dark gray bars, third from the left) or with ApoFasL-060 and cross-linking antibody (medium gray bars, each on the right), depending on the time after administration (2h, 4h, 24h).
  • saline filled bars
  • ApoFasL-060 20 ⁇ g
  • ApoFasL-060 dark gray bars, third from the left
  • ApoFasL-060 and cross-linking antibody medium gray bars, each on the right
  • ApoFasL-060 prevents the lethal effects of the agonistic anti-Fas -Antibody J02 in mice.
  • the inhibitory effect of ApoFasL-060 (medium gray bars) is canceled by cross-linking antibodies.
  • FIG. 4 shows the effect of ApoFasL-267 after liver damage induced by oligomerized FasL.
  • Figure 4 shows the results from experiments in which the mice were intravenously injected with either saline or 25 ⁇ g of ApoFasL-267 prior to the intravenous injection of oligomerized FasL (FasL-199).
  • the serum titers of ALT (filled bars) and AST (open bars) were analyzed after four hours. Again the bars represent the respective titers in U / ml.
  • FIG FasL-267 show the results Gift of agonistic, ie FasL triggering apoptosis
  • the left-hand plot represents the comparative experiment without administration of agonistic FasL.
  • the results of experiments with FasL-199 without protective ligands and of FasL-199 in combination with protective ligands are thus shown in FIG FasL-267 shown
  • FIG. 5 shows the effect of soluble FasL in the case of AAP-induced hepatitis.
  • the mice were injected intravenously with either ApoFasL-267 (Figure 5A) or ApoFasL-060 ( Figures 5B and 5C) prior to the intraperitoneal injection of AAP (300 mg / kg).
  • the titres (U / ml) of ALT (filled bars) and AST (open bars) are plotted in FIGS. 5A and 5B, each five hours after the Injection were measured.
  • the left-hand plots in FIGS. 5A and 5B correspond to the comparative tests, while the right-hand plots (FIG. 5A) and in FIG. 5B the middle and right-hand plots represent the results after administration of the inhibitors according to the invention.
  • FIG. 5C shows the relative decrease in the aminotransferase titers compared to sham-treated (KontroU) animals (100%).
  • FIG. 6 shows the effect of ApoFasL-267 and ApoFasL-060 on a mouse liver treated with AAP.
  • the mice were treated as described above in FIG. 5, 24 hours after the hepatitis induction, the livers were dissected and histologically evaluated in FIG. 6 three images of histological sections (addition of AAP, addition of AAP and ApoFasL-267 and finally a comparative approach (control) after addition of saline).
  • Treatment of the mice with ApoFasL-267 prevents liver damage, as can be seen from a comparison with the histological section from the control animals.
  • the livers of animals treated exclusively with AAP show necrosis and apoptosis in the center Venous area, sinusoidal inflamed blood and vacuolated hepatocytes.
  • FIG. 7A shows the cDNA sequence and the amino acid sequence derived therefrom for the Fas chimera Fas-ACRP30 (MKB216).
  • the construct contains amino acids 17 to 172 of the extracellular domain of Fas (ie the Fas receptor), fused via a linker of 14 amino acids to the complete oligomerization domain of murine ACRP30 (amino acids 18 to HO).
  • the amino terminal also contains an Ig heavy chain signal sequence and a Flag Tg. Furthermore, the restriction sites are indicated in the figure.
  • FIG. 7B shows a restriction map with the specified interfaces of the construct from FIG. 7A.
  • the inhibitory effect of Fas-ACRP30 in vitro against FasL-mediated apoptosis in A20 cells is documented in FIG. 8.
  • the absorpti- on at 490 nm (measure of the survivability of the cells; cf. also FIG. 2), while the concentration of the respective fusion protein is plotted in ng / ml on the x-axis.
  • the inhibitory effect of Fas-ACRP30 was compared to that of Fas -Fc, a dimeric form of Fas, and that of Fas-COMP, a pentameric form of Fas.
  • the FasL DCLitemaer FasL-199 according to the invention served as an apoptosis-inducing agent.
  • the Fas-ACRP30 construct inhibits FasL-induced apoptosis with an ICs ⁇ value of 80 ng / ml. This value is comparable to that of the pentameric Fas derivative Fas-COMP (35 ng / ml), while the IC 50 value for (dimeric) Fas-Fc is more than 1 ⁇ g / ml
  • the expression vector for FasL-199 was constructed in the following manner. First, a PCR amplification using the oligonucleotides JT1147 (ACA ATG CAT GAA GAT GAC GTT ACT AC) and JT1148 (AGA CTG GAG AGC GGC TTC) was carried out using the EST clone AA673154 TCC AGG) The sequence coding for amino acids 18 to 111 of the murine ACRP30, framed by the restriction sites Nsil and Pstl, is cloned into the Pstl site of the vector coding for trimeric FasL (such that the fused Nsil / Pstl site on the 5th Side of the coding sequence).
  • the vector for expressing the fusion protein FasL-167 (with the AS 44-111 from mACRP30) was amplified with the aid of the alternative 5'-oligonucleotide JT1421 (AAA ATG CAT GCA GGC ATC CCA GGA C).
  • the PCR product was converted into a PCR "blunt" system ligated and the Nsi / Pstl cassette subcloned into the FasL-containing vector as described above.
  • Other fusion proteins with alternative TNF cytokines in combination with ACRP30 were obtained by substituting the corresponding sequence of FasL in the expression vector FasL-ACRP30 created with the respective ligand sequence in the restriction sites Pstl and EcoRI
  • HEK293 cells were stably transfected using the calcium phosphate method. After three days of incubation, the HEK293 cells were cultivated for two weeks in a selection medium which contained 800 ⁇ g ml G418 (see also aa0 : Schneider et al., J. Exp. Med. 1998). These stably transfected clones were removed and distributed in 96-well plates in selection media. The supernatants were examined for the presence of the recombinant protein using the anti-flag Western blot technique
  • the stably transfected cells were bottled for 10 to 14 days in 800 ml of a non-selective medium.
  • the culture was centrifuged and the supernatant was filter-sterilized.
  • Fusion proteins from FasL with murine ACRP30 (FasL-267 or FasL-199) were then purified in the following manner.
  • the supernatants were mixed with NaCl and CaCl 2 (final concentrations of 150 mM or 2 mM) and the pH was adjusted to 7.0 using hydrochloric acid / sodium hydroxide solution.
  • the recombinant protein was then applied to a 1 ml M2 agarose column (Sigma, Switzerland) (0.5 ⁇ / ra, 48 h , 4 ° C), the column with 10 volumes of TBS containing 2 mM CaCl 2 , and finally in TBS-EDTA (10 mM) (0.1 ml / min, 4 ° C) or 50 mM citrate-NaOH (pH 2.5) (1 ml / min, 4 ° C.) and optionally neutralized with 0.2 volumes of 1 M Tris-HCl (pH 8).
  • the buffer was against PBS in concentrators with a 30 kDA limit (Millipore )
  • concentration of purified proteins was determined by the bicmonchonic acid method (Pierce Chemical Co., Rockford, PL, USA) using rmder serum albumin as standard and the purity of the samples was determined by SDS-PAGE and Coomassie Blue staining
  • the human T lymphoplastoma Jurkat cells, BJAB Burkitt lymphoma cells or Raji cells were grown in RPMI accompanied by 10% FCS.
  • the human embryonic kidney cells 293 were cultivated in a DMEM multi-substance mix F12 (1: 1), enriched with 2% FCS. All media contained antibiotics (penicillin and streptomycin at 5 ⁇ gml each and neomycin at 10 ⁇ g / ml).
  • the cytotoxic assay was essentially as previously described by Schneider et al. (J. Biol. Chem. 272: 18827-18833, 1997). 50,000 cells were incubated for 16 hours in 100 ⁇ l medium, the medium displaying the indicated ligand concentrations in the presence or absence of 1 ⁇ g ml of M2 antibodies The cell survival rates were determined using PMS / MTS (phenanzin methosulfate 3- [4,5-dimemylthiazol-2-yl] -5- [3-carboxymethoxyphenyl] -2- [4-sulfophenyl] -2H-tetrazolium, salt) (Promega Corp., Madison, WI). Color development was allowed for the time required (typically 1-3 hours).
  • the absorbance was measured at 490 ⁇ m.
  • the optical density at 490 nm is a measure of the viability of the cells (high optical density corresponds to a low apoptotic effect of the added substances and thus a high viability of the cells).
  • mice were injected intravenously into female Balb / c mice (8 to 10 weeks old). The mice were bled out at the specified time intervals with subsequent quantification of the titers of the aminotransferases AST and ALT (aspartate aminotransferase and alanine aminotransferase)
  • anti-Flag-MI and anti-Flag-M2 antibodies coupled to agarose were purchased from Sigma (Buchs, Switzerland).
  • Antibodies J02 were purchased from Pharmingen and cell culture reagents from Life Sciences (Basel, Switzerland).
  • the affinity of ApoFasL-267 and FasL-199 was determined using a composition assay.
  • the monoclonal anti-Fas antibodies ZB4 were labeled with 100 ⁇ Ci (1251) by the iodo gene method (Pierce, Rockford, IL) resulted in a specific activity of 1.5 ⁇ Ci / ⁇ g protein.
  • 1x105 Bjab cells were incubated with radiolabelled ZB4 and unlabeled competitors in serial dilution (100 ⁇ g / ml to 10 ng / ml) for 1 h at 37 ° C. After three washes with cold PBS, which contained 1% BSA, the was the bound radioactivity was determined with a ⁇ -counter and expressed as a percentage of bound cpm. All experiments were carried out in triplicate
  • Ausfuhtungsbeispiel A recombinant fusion protein (1, FasL-199) was expressed, which amino acids 139 to 281 of hFasL (h: human) as component A and N-terminal of the Amino acid 139 of component A as component B had a 94 AA long sequence (AS 18 to 111 of mACRP30).
  • a flag sequence with the amino acids DYKDDDDK and a linker sequence GPGQVQLQLH arranged between the flag tag and component B was expressed (see FIG. 1) at the N-terminus of the fusion protein (N-terminal of component B)
  • Components A and B are separated by the linker sequence LQ
  • Fusion protein (1) therefore differed from fusion protein (2) by a deletion which comprised the specific linker and amino acids 103 to 138 of hFasL (FIG. 1).
  • the vector construction of the fusion proteins (1) and (2) was carried out according to the procedure described above.
  • the expression and purification of the fusion proteins was carried out according to the method shown in (b),
  • the degree of multi- or oligomerization of the purified fusion proteins (1 or 2) was determined by electron microscopy. It was found that FasL-199 as hexamer (2x3mer), corresponding measurements for FasL-267 gave results for a trimer and for ApoFasL-060 as well a hexamer.
  • Bjab-Burkitt lymphoma cells grown according to (c) were removed and subjected to a cytotoxic assay according to (d).
  • the assay was carried out in each case with increasing concentrations of trimerized fusion proteins ApoFasL-060 and ApoFasL-267 in the presence or absence of anti-Flag-M2 antibodies (Sigma, Buchs, Switzerland) (FIG. 2A), by reducing the absorbance at OD 490 nm was determined.
  • the inhibitors ApoFasL-060 and ApoFasL-267 used are shown in FIG. 1 (see first exemplary embodiment).
  • mice were injected with agonistic J02 anti-Fas antibodies, which in the mice treated in this way led to the exit from fulminant liver failure. Hepatolysis in these mice was demonstrated by the high serum titers of amino transferases (AST and ALT).
  • the mice were pretreated with ApoFasL-060 (1 mg / kg), whereby the animal after administration of J02- Antibodies were saved from the liver failure (hepatolysis) triggered by them (see FIG. 3A).
  • the protective effect of ApoFasL-060 was dose-dependent.
  • the FasL-induced hepatolysis is very high in the animals used for the control to be observed quickly (within two hours) after administration of FasL-199, namely with arninotransferase titers, which are increased by a factor of 10.
  • the pretreatment of the animals with ApoFasL-267 therefore prevents according to the AST or ALT serum titer certain liver damage to the animals. 4. Rest example
  • Acetaminophen (AAP), a pain reliever, is known to induce fulminant liver failure.
  • the molecular mechanism is based on Fas-mediated apoptosis. It was therefore examined in the present exemplary embodiment whether trimeric ApoFasL-267 and or hexameric ApoFasL-060 can protect the liver cells from AAP-induced cell death.
  • AAP a sublethal dose of AAP (0 g kg) was injected intraperitoneally into the mice. Five hours later, any liver damage was determined by determining the serum titers of ALT and AST. The ALT and AST titers were determined in accordance with the IFCC guidelines (International Federation of Clinical Chemistry) determined as an enzymatic test.
  • Fig. 6A The AAP-induced liver damage was examined histologically (Fig. 6A). The following are worth mentioning: necrosis and apoptosis in the central area of the venula, sinusoidal inflammation of blood, vacuolated hepatocytes. In contrast, as shown in FIG. 6B, no such liver damage is recognizable in the case of pretreatment with ApoFasL-267 (or ApoFasL-060, not shown). 5th exemplary embodiment
  • Fas-ACRP30 a fusion protein from the extracellular domain of the Fas receptor (amino acids 17 to 172) and the complete oligomerization domain of murine ACRP30 (amino acids 18 to HO), which linkers of 14 amino acids with one another are connected, produced ( Figure 7).
  • the recombinant protein was analyzed by SDS-PAGE and had an apparent molecular weight of 55 kDa under reducing conditions or 150 kDa under non-reducing conditions. From this it can be concluded that the construct MKB216 (hereinafter referred to as Fas-ACRP30) is essentially a hexamer (2x3mer)
  • FasL-sensitive A20 cells were preincubated with increasing concentrations of Fas-ACRP30 before the addition of oligomerized FasL.
  • the particularly effective FasL oligomer served in present experiment, the construct according to the invention FasL-199.
  • Fas-ACRP30 compared with that of a dimeric form of Fas (Fas-Fc) and a pentameric form of Fas (Fas-COMP).
  • Fas-ACRP30 is an effective inhibitor of FasL-mediated apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines hybrides recombinées possédant la propriété de pouvoir former des trimères. Ces protéines hybrides recombinées présentent au moins un composant A possédant des propriétés biologiques et au moins un composant B possédant la propriété de former des trimères. L'invention concerne également des trimères de ces protéines hybrides recombinées, ainsi que l'utilisation de ces trimères pour produire un médicament ou pour établir un diagnostic in vitro ou encore pour produire un agent de diagnostic in vitro. L'invention concerne en outre des séquences d'ADN qui codent pour une telle protéine hybride, ainsi que des vecteurs d'expression et des cellules hôtes qui contiennent cette séquence d'ADN ou ce vecteur d'expression.
EP02769144A 2001-05-08 2002-05-08 Proteines hybrides recombinees et leurs trimeres Withdrawn EP1385966A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10122140A DE10122140A1 (de) 2001-05-08 2001-05-08 Rekombinante Fusionsproteine und deren Trimere
DE10122140 2001-05-08
PCT/EP2002/005103 WO2002090553A2 (fr) 2001-05-08 2002-05-08 Proteines hybrides recombinees et leurs trimeres

Publications (1)

Publication Number Publication Date
EP1385966A2 true EP1385966A2 (fr) 2004-02-04

Family

ID=7683900

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02769144A Withdrawn EP1385966A2 (fr) 2001-05-08 2002-05-08 Proteines hybrides recombinees et leurs trimeres

Country Status (12)

Country Link
US (1) US20040197876A1 (fr)
EP (1) EP1385966A2 (fr)
JP (1) JP2004534529A (fr)
CN (1) CN1602358A (fr)
BR (1) BR0209471A (fr)
CA (1) CA2452245A1 (fr)
DE (1) DE10122140A1 (fr)
IL (1) IL158751A0 (fr)
MX (1) MXPA03010263A (fr)
PL (1) PL367031A1 (fr)
WO (1) WO2002090553A2 (fr)
ZA (1) ZA200308589B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
ATE438662T1 (de) 2003-03-26 2009-08-15 Apogenix Gmbh Verbesserte fc-fusionsproteine
US20050143297A1 (en) * 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
US7268116B2 (en) * 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
CA2619048A1 (fr) 2005-08-15 2007-02-22 The Regents Of The University Of California Ligands fas actives par vegf
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
CA2860950C (fr) 2007-07-10 2017-08-01 Apogenix Gmbh Proteines de fusion collectines de la superfamille des tnf
AU2013203061B2 (en) * 2007-07-10 2016-07-28 Apogenix Ag TNF superfamily collectin fusion proteins
EP2540740B1 (fr) * 2008-06-17 2014-09-10 Apogenix GmbH Récepteurs multimériques TNF
US20120015000A1 (en) * 2008-06-30 2012-01-19 David Lanar Malaria vaccine of self-assembling polypeptide nanoparticles
WO2010010051A1 (fr) * 2008-07-21 2010-01-28 Apogenix Gmbh Molécules à une seule chaîne
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
WO2014100913A1 (fr) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
JP2014124186A (ja) * 2012-12-26 2014-07-07 Industrial Technology Research Institute 多価抗体フラグメントおよびその三量体化複合体
WO2014121099A1 (fr) * 2013-01-31 2014-08-07 Thomas Jefferson University Protéine de fusion agoniste des cd40 ox40 et ses utilisations
RU2016116732A (ru) * 2013-10-09 2017-11-15 Сэллект Байотерапьютикс Лтд. Активация гемопоэтических клеток-предшественников путем предтрансплантационного воздействия лигандами рецепторов смерти
CN103739714B (zh) * 2013-12-30 2016-06-01 江苏众红生物工程创药研究院有限公司 TNFα与DC-SIGN的融合蛋白及其应用
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2017068185A1 (fr) * 2015-10-23 2017-04-27 Apogenix Ag Protéines agonistes du récepteur gitr à chaîne unique
JP2016210791A (ja) * 2016-08-03 2016-12-15 アポゲニクス アーゲー 三量体形成融合タンパク質
US11377490B2 (en) 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
AU2019361030A1 (en) * 2018-10-16 2021-05-27 Board Of Regents, The University Of Texas System Compositions for and methods of producing tumor organoids
WO2021249116A1 (fr) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin contre le coronavirus, procédés et utilisations associées
WO2021249010A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions, procédés et utilisations de diagnostic de coronavirus
WO2021249013A1 (fr) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Compositions de vaccin, procédés et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
JP2000125872A (ja) * 1998-09-07 2000-05-09 Terumo Corp 三量体キメラタンパク質およびキメラタンパク質を含有するコラーゲンマトリックス
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
WO2002079415A2 (fr) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02090553A2 *

Also Published As

Publication number Publication date
WO2002090553A3 (fr) 2003-05-01
ZA200308589B (en) 2004-07-12
IL158751A0 (en) 2004-05-12
US20040197876A1 (en) 2004-10-07
BR0209471A (pt) 2004-07-06
MXPA03010263A (es) 2005-03-07
DE10122140A1 (de) 2002-11-28
CA2452245A1 (fr) 2002-11-14
CN1602358A (zh) 2005-03-30
JP2004534529A (ja) 2004-11-18
PL367031A1 (en) 2005-02-21
WO2002090553A2 (fr) 2002-11-14

Similar Documents

Publication Publication Date Title
WO2002090553A2 (fr) Proteines hybrides recombinees et leurs trimeres
EP1246925B1 (fr) Bimere ou oligomere d'un dimere, trimere, quatromere ou pentamere de proteines de fusion de recombinaison
DE60034579T3 (de) Baff rezeptor (bcma), ein immunoregulatorisches mittel
DE69630710T2 (de) Humaner tumornekrosefaktor delta und epsilon
DE60128216T2 (de) Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
EP1317488B1 (fr) Activation localement specifique, par l'intermediaire d'anticorps, d'une zytokine pro-apoptose : amaize (antibody-mediated apoptosis inducing zytokine)
DE60222882T2 (de) Peptide und verwandte moleküle, die an tall-1 binden
DE69233351T2 (de) Multimere der löslichen Formen der TNF-Rezeptoren, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE60028830T2 (de) Anti-april antikörper und hybridomazellen
DE69635480T2 (de) Apoptosis induzierendes cytokin
DE69836956T2 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
DE69333027T2 (de) Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
WO2005103077A1 (fr) Polypeptides recombines des membres de la famille des ligands tnf et leur utilisation
DE69927147T2 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69733773T2 (de) Fas ANTIGEN-DERIVATE
DE69736597T2 (de) Gdnf rezeptor
DE602004006871T2 (de) Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
DE69924009T2 (de) Methode zur verstärkung der biologischen aktivität von liganden
DE69931944T2 (de) Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
DE10247755B4 (de) Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
DE60037648T2 (de) Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten
WO2000047736A1 (fr) Variantes de polypeptides a capacite amelioree de liaison de l'heparine
EP1516054A2 (fr) Structures de fusion contenant des parties actives de ligands tnf
EP2552488A1 (fr) Protéines de fusion et leurs utilisations
DE602004008146T2 (de) Verwendung von TNF-Liganden Multimere mit reduzierter Toxicität zur Behandlung von proliferativen Krankheiten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061004